Glutamate transporters function to maintain low levels of extracellular glutamate and play an important role in synaptic transmission at many synapses. Disruption of glutamate transporter function or expression can result in increased extracellular glutamate levels. Alterations in glutamate transporter expression have been reported in human epilepsy and animal seizure models. Functional electrophysiological changes that occur when transporter expression is disrupted in chronic epilepsy models have not been examined. Here, we used a freeze-induced model of cortical dysplasia to test the role of glutamate transporters in synaptic hyperexcitability. We report that inhibiting glutamate transporters with the non-selective antagonist, DLthreo-β-benzylozyaspartic acid (TBOA) preferentially prolongs postsynaptic currents (PSCs) and decreases the threshold for evoking epileptiform activity in lesioned compared to control cortex. The effect of inhibiting uptake is mediated primarily by the glia glutamate transporter (GLT-1) since the selective antagonist dihydrokainate (DHK) mimicked the effects of TBOA. The effect of uptake inhibition is mediated by activation of N-methyl-D-aspartate (NMDA) receptors since D-(−)-2-amino-5-phosphonovaleric acid (APV) prevents TBOA-induced effects. Neurons in lesioned cortex also have a larger tonic NMDA current. These results indicate that chronic changes in glutamate transporters and NMDA receptors contribute to hyperexcitability in cortical dysplasia.
Introduction
Cortical dysplasia is associated with disruption of normal cortical cytoarchitecture and is often observed in pediatric epilepsy (Farrell et al., 1992; Mischel et al, 1995; Prayson et al., 1995) . Improvements in neuroimaging techniques have enabled observation of malformations during life and point to a higher incidence than previously suspected (Palmini et al., 1991a, b; Barkovich and Kjos, 1992; Raymond et al., 1995) . It has been reported that approximately 43% of patients undergoing surgery for intractable seizures have cortical malformations (Brannstrom et al., 1996) . Current antiepileptic drugs are often ineffective in patients with cortical malformations (Olivier et al., 1996; Porter et al., 2003; Barkovich and Raybaud 2004) . In an effort to understand the relationship between structural abnormalities and seizure activity, several animal models of cortical malformations have been developed. These include prenatal methylazoxmethanol (MAM) (Baraban and Schwartzkroin, 1995, 1996; Chevassus et al., 1998 ), prenatal irradiation (Roper, 1998 and freeze-induced focal cortical dysplasia (Dvorak et al., 1978) models. Transcortical freeze-lesions in the early postnatal period produce a four layered cortex (Dvorak and Feit, 1977) associated with marked gliosis (Bordey et al., 2001 ). Many of the electrophysiological and anatomical features of human cortical dysplasia are reproduced in the freeze-lesion model (Dvorak and Feit 1977 , Jacobs et al., 1996 , 1999a Luhmann and Raabe, 1996; DeFazio and Hablitz, 1998) . Freeze-lesion animals show hyperexcitability predominantly in the area adjacent (0.5 to 2.5 mm lateral) to the microsulcus (Hablitz and DeFazio 1998; Jacobs et al., 1996 Jacobs et al., , 1999a Luhmann et al., 1998a,b; Redecker et al., 1998; Prince et al., 1997) .
Glutamate transporters act to remove synaptically released glutamate in order to maintain low glutamate levels in the extracellular space (Nicholls and Attwell 1990; Lipton and Rosenberg, 1994; Tanaka et al., 1997; Rusakov and Kullmann 1998; Danbolt 2001) and to prevent neurotoxicity (Choi, 1988; Choi et al., 1987; Olney and Ho, 1970) . Five subtypes of sodium-dependent high-affinity glutamate transporters have been identified. In humans, they are designated excitatory amino acid transporters (EAAT) 1-5 (Storck et al., 1992; Pines et al., 1992; Kanai and Hediger, 1992; Fairman et al., 1995; Arriza et al., 1997) . The rodent homologues of EAAT1-3 are termed GLAST, GLT-1 and EAAC1 whereas EAAT4-5 maintain the same nomenclature. GLAST and GLT-1 are predominantly glial transporters with high expression in neocortex (Lehre et al., 1995) and are responsible for N90% of the total glutamate uptake (Tanaka et al., 1997) . There is considerable evidence supporting a dominant role of glial transporters in mediating the majority of glutamate uptake (Haugeto et al., 1996; Rothstein et al., 1996; Marcaggi and Attwell 2004) . Neurobiology of Disease 32 (2008) 254-261 
